Aprea Therapeutics, Inc. 8-K

What Happened

• On March 16, 2026, Aprea Therapeutics, Inc. (APRE) filed an 8-K (Item 2.02 and Item 8.01) to announce its financial results for the three and twelve months ended December 31, 2025, and to provide an operational update. The company furnished a press release and updated its corporate presentation as exhibits to the filing.

Key Details

• Filing date: March 16, 2026 (8-K filed by Aprea Therapeutics, Inc.).
• Period covered: financial results for the three months and the twelve months ended December 31, 2025.
• Exhibits: Exhibit 99.1 — press release announcing the results; Exhibit 99.2 — updated corporate presentation (March 2026).
• Filing signed by President & CEO Oren Gilad, Ph.D.

Why It Matters

• The 8-K makes Aprea’s latest quarterly and full-year 2025 results and corporate update public, giving investors current information on the company’s performance and strategic progress.
• Investors should review the attached press release and slide deck for specific financial metrics (revenue, net loss, cash/runway, pipeline updates) and management commentary to assess near-term outlook and financing or operational needs.